Huntington's Disease

Neurology and Clinical Neuroscience: Text with CD-ROM

Volumn , Issue , 2006, Pages 879-885

  Driver Dunckley, Erika ^a,b   Caviness, John N ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907052183     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03354-1.50071-7     Document Type: Chapter

References (34)

1. Bonelli RM, Hofmann P A review of the treatment options for Huntington's disease. Expert Opin Pharmacother 2004, 5:767-776.
2. Caviness JN Huntington's disease and other choreas. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician 2000, 321-330. Humana Press, Totowa, NJ. C.H. Adler, J.E. Ahlskog (Eds.).
3. Hersch SM Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. Curr Opin Neurol 2003, 16:501-506.
4. Li S-H, Li X-J Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004, 20:146-154.
5. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Huntington's Disease Collaboration Research Group. Cell 1993, 72:971-983.
6. Huntington G On chorea. George Huntington, M.D. J Neuropsychiatry Clin Neurosci 2003, 15:109-112.
7. Okun MS Huntington's disease: what we learned from the original essay. Neurologist 2003, 9:175-179.
8. Okun MS Americo Negrette (1924 to 2003): diagnosing Huntington disease in Venezuela. Neurology 2004, 63:340-343.
9. Cattaneo E, Rigamonti D, Goffredo D, et al. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001, 24:182-188.
10. Fahn S Huntington's disease. Merritt's Neurology 2000, 659-662. Lippincott Williams & Wilkins, New York. 10th ed. L.P. Rowland (Ed.).
11. Myers RH, MacDonald ME, Koroshetz WJ, et al. De novo expansion of a (CAG)(n) repeat in sporadic Huntington's disease. Nat Genet 1993, 5:168-173.
12. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
13. Bates G Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003, 361:1642-1644.
14. Hersch SM Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. Curr Opin Neurol 2003, 16:501-506.
15. Li S-H, Li X-J Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004, 20:146-154.
16. Haddad MS, Cummings JL Neuropsychiatry of the basal ganglia. Psychiatr Clin North Am 1997, 20:791-807.
17. Caviness JN, Kurth M Cortical myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord 1997, 12:1046-1051.
18. Lasker AG, Zee DS Ocular motor abnormalities in Huntington's disease. Vision Res 1997, 37:3639-3645.
19. Schoenfeld M, Myers RH, Cupples LA, et al. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1984, 47:1283-1287.
20. Pratley RE, Salbe AD, Ravussin E, et al. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 2000, 47:64-70.
21. Martin JB, Gusella JF Huntington's disease: pathogenesis and management. N Engl J Med 1986, 315:1267-1276.
22. Caviness JN Huntington's disease and other choreas. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician 2000, 321-330. Humana Press, Totowa, NJ. C.H. Adler, J.E. Ahlskog (Eds.).
23. Starkstein SE, Brandt J, Bylsma F, et al. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neuroradiology 1992, 34:487-489.
24. Folstein SE The psychopathology of Huntington's disease. Res Publ Assoc Res Nerv Ment Dis 1991, 69:181-191.
25. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003, 61:925-930.
26. Huntington Study Group A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
27. Peyser CE, Folstein M, Chase GA, et al. Trial of D-alphatocopherol in Huntington's disease. Am J Psychiatry 1995, 152:1771-1775.
28. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global barin ischemia. Proc Natl Acad Sci U S A 1998, 95:15769-15775.
29. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003, 53:186-196.
30. Huntington Study Group Minocycline safety and tolerability in Huntington disease. Neurology 2004, 63:547-549.
31. Bonelli RM, Hodl AK, Hofmann P, et al. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004, 19:337-342.
32. Peschanski M, Dunnett SB Cell therapy for Huntington's disease, the next step forward. Lancet Neurol 2002, 1:81.
33. Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004, 56:290-294.
34. Blum D, Hourez R, Galas MC, et al. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol 2003, 2:366-374.